JPY 166.0
(-1.78%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.08 Billion JPY | 50.33% |
2022 | 725.05 Million JPY | -14.23% |
2021 | 845.34 Million JPY | 20.97% |
2020 | 698.78 Million JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 341.67 Million JPY | 21.14% |
2024 Q2 | 342.53 Million JPY | 0.25% |
2023 Q4 | 282.04 Million JPY | -11.0% |
2023 Q3 | 316.9 Million JPY | 47.81% |
2023 FY | 1.08 Billion JPY | 50.33% |
2023 Q1 | 276.6 Million JPY | 204.85% |
2023 Q2 | 214.4 Million JPY | -22.49% |
2022 Q4 | -263.81 Million JPY | 0.0% |
2022 FY | 725.05 Million JPY | -14.23% |
2021 FY | 845.34 Million JPY | 20.97% |
2020 FY | 698.78 Million JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
KOHJIN BIO CO LTD | 1.28 Billion JPY | 15.144% |
PRISM BioLab Co.,LTD | 576.81 Million JPY | -88.96% |
GNI Group Ltd. | 9.32 Billion JPY | 88.308% |
Linical Co., Ltd. | 2.7 Billion JPY | 59.709% |
Trans Genic Inc. | 2.15 Billion JPY | 49.535% |
MEDINET Co., Ltd. | 1.49 Billion JPY | 26.906% |
Soiken Holdings Inc. | 3.07 Billion JPY | 64.509% |
Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 41.305% |
AnGes, Inc. | 8.9 Billion JPY | 87.756% |
OncoTherapy Science, Inc. | 943.08 Million JPY | -15.574% |
Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 94.32% |
Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -163.917% |
NanoCarrier Co., Ltd. | 975.37 Million JPY | -11.747% |
Carna Biosciences, Inc. | 2.56 Billion JPY | 57.549% |
CanBas Co., Ltd. | 278 Million JPY | -292.069% |
D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 4.519% |
RaQualia Pharma Inc. | 1.81 Billion JPY | 40.045% |
Chiome Bioscience Inc. | 1.6 Billion JPY | 32.038% |
Kidswell Bio Corporation | 2.37 Billion JPY | 54.089% |
PeptiDream Inc. | 9.68 Billion JPY | 88.749% |
Oncolys BioPharma Inc. | 1.96 Billion JPY | 44.407% |
Ribomic Inc. | 1.1 Billion JPY | 1.423% |
SanBio Company Limited | 4.53 Billion JPY | 75.987% |
Healios K.K. | 3.48 Billion JPY | 68.742% |
BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 5.61% |
Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 18.323% |
Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 22.338% |
StemRIM | 2.07 Billion JPY | 47.497% |
CellSource Co., Ltd. | 1.96 Billion JPY | 44.489% |
FunPep Company Limited | 313.82 Million JPY | -247.316% |
Kringle Pharma, Inc. | 958.01 Million JPY | -13.772% |
Stella Pharma Corporation | 963.98 Million JPY | -13.067% |
TMS Co., Ltd. | 943.25 Million JPY | -15.552% |
Cuorips Inc. | 598.11 Million JPY | -82.23% |
K Pharma,Inc. | 543.94 Million JPY | -100.38% |
Takara Bio Inc. | 23.9 Billion JPY | 95.44% |
ReproCELL Incorporated | 1.51 Billion JPY | 28.009% |
PhoenixBio Co., Ltd. | 1.18 Billion JPY | 7.942% |
StemCell Institute Inc. | 1.16 Billion JPY | 6.21% |
Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 28.4% |
CellSeed Inc. | 804.93 Million JPY | -35.409% |